On Thursday, the morning session of the Symposium focused on the best treatment options for hormone sensitive tumors (tumors that are ER and/or PR-positive).Today, the focus turned to tumors that are HER2-positive.Trastuzumab (brand name Herceptin) was a breakthrough when it was first introduced as a treatment for HER2-positive tumors. But its widespread use has demonstrated [...][Continue Reading...]